RxDoctor Payments Data

Michelle Ehrlich, MD

Dermatology · Manhattan Beach, CANPI 1134244635

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $464,195 of the $734,624 with a category attached, or 63.2%. 46 manufacturers reported payments, led by LEO Pharma Inc. at 24.9% of the total. 2025 is the largest year on record at $257,337, 5.0 times the $50,998 reported in 2019. Among dermatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$734,624in general payments, 2019–2025

Across 1,482 payments — averaging $495.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • LEO Pharma Inc.$183K
  • Amgen$122K
  • Galderma Laboratories, L.p.$84K
  • Pfizer$83K
  • Arcutis Biotherapeutics, Inc.$78K
  • Incyte Corporation$66K
  • plus $119K from 40 others
$523in research payments, 2019–2025

Across 1 payment — averaging $523.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$523

What the payments were for

  • Consulting fees$151,96921%
  • Speaking & faculty fees$464,19563%
  • Travel & lodging$83,70211%
  • Food & beverage$34,6395%
  • Education$1200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$734,624 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$60,836
Medicare patients
131
Services billed
1,236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdbryTralokinumab-Ldrm19$73,339
Tavaborole26$33,431
ZoryveRoflumilast13$11,076
Metronidazole19$1,349
Cimetidine13$409
Ketoconazole26$307
ValacyclovirValacyclovir Hcl13$221
Doxycycline Hyclate13$203
Montelukast Sodium19$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
LEO Pharma Inc.Adbry$182,846$73,33919 claims
Arcutis Biotherapeutics, Inc.Zoryve$78,097$11,07613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,875 dermatology providers in California.

Other dermatology in Manhattan Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →